PolyPeptide Group AG
Stock Forecast, Prediction & Price Target

	Passed			Analyst forecast
Metric	12/31/2021	12/31/2022	12/31/2023	12/31/2025	12/31/2026
Revenue % change YoY	CHF282.12M N/A	CHF280.97M -0.40%	CHF320.37M 14.02%	Avg: CHF389.93M Low: CHF389.93M High: CHF389.93M avg. 21.71%	Avg: CHF444.66M Low: CHF444.66M High: CHF444.66M avg. 14.03%
Net Income % change YoY	CHF47.25M N/A	CHF7.76M -83.56%	CHF-51.44M -762.28%	Avg: CHF16.36M Low: CHF16.36M High: CHF16.36M avg. 131.81%	Avg: CHF34.53M Low: CHF34.53M High: CHF34.53M avg. 111.06%
EBITDA % change YoY	CHF83.45M N/A	CHF33.05M -60.39%	CHF-22.15M -167.01%	Avg: CHF66.18M Low: CHF66.18M High: CHF66.18M avg. 398.79%	Avg: CHF75.47M Low: CHF75.47M High: CHF75.47M avg. 14.03%
EPS % change YoY	$1.47 N/A	$0.24 -83.67%	-$1.56 -750.00%	Avg: $0.5 Low: $0.5 High: $0.5 avg. 131.81%	Avg: $1.05 Low: $1.05 High: $1.05 avg. 111.06%
Operating Expenses % change YoY	CHF37.03M N/A	CHF42.34M 14.32%	CHF41.11M -2.90%	Avg: CHF38.53M Low: CHF38.53M High: CHF38.53M avg. -6.26%	Avg: CHF43.94M Low: CHF43.94M High: CHF43.94M avg. 14.03%

FAQ

Wall Street analysts estimate the annual average earnings growth rate of 121.44% in 2025-2026.

We have gathered data from N/A analysts. Their low estimate is 16.36M, average is 16.36M and high is 16.36M.

Wall Street analysts forecast annual average revenue growth of 17.87% in 2025-2026.

We have gathered data from N/A analysts. Their low revenue estimate is CHF389.93M, average is CHF389.93M and high is CHF389.93M.

Wall Street analysts forecast annual average earnings growth of 121.44% in 2025-2026.

We have gathered data from N/A analysts. Their low earnings per share estimate is $0.5, average is $0.5 and high is CHF0.49.